Published August 19, 2020 | Version v1
Journal article Open

Nearest-neighbor amino acids of specificity-determining residues influence the activity of engineered Cre-type recombinases

  • 1. Structural Bioinformatics, BIOTEC, TU Dresden, Tatzberg 47-51, 01307, Dresden, Germany
  • 2. University Carl Gustav Carus and Medical Faculty, UCC, Medical Systems Biology, TU Dresden, Fetscherstrasse 74, Dresden, Germany

Description

Abstract

The tyrosine-type site-specific DNA recombinase Cre recombines its target site, loxP, with high activity and specificity without cross-recombining the target sites of highly related recombinases. Understanding how Cre achieves this precision is key to be able to rationally engineer site-specific recombinases (SSRs) for genome editing applications. Previous work has revealed key residues for target site selectivity in the Cre/loxP and the related Dre/roxrecombinase systems. However, enzymes in which these residues were changed to the respective counterpart only showed weak activity on the foreign target site. Here, we use molecular modeling and dynamics simulation techniques to comprehensively explore the mechanisms by which these residues determine target recognition in the context of their flanking regions in the protein–DNA interface, and we establish a structure-based rationale for the design of improved recombination activities. Our theoretical models reveal that nearest-neighbors to the specificity-determining residues are important players for enhancing SSR activity on the foreign target site. Based on the established rationale, we design new Cre variants with improved rox recombination activities, which we validate experimentally. Our work provides new insights into the target recognition mechanisms of Cre-like recombinases and represents an important step towards the rational design of SSRs for applied genome engineering.

Files

Soni et al 2020.pdf

Files (4.1 MB)

Name Size Download all
md5:14971ae76045d2cf301bf2012432ab00
4.1 MB Preview Download

Additional details

Funding

UPGRADE – Unlocking Precision Gene Therapy 825825
European Commission